Suppr超能文献

重症监护病房中患有严重艰难梭菌结肠炎的患者结肠内给予万古霉素

Intracolonic Administration of Vancomycin in Intensive Care Unit Patients with Severe Clostridium Difficile Colitis.

作者信息

Teixeira Alex, Tripathi Kartikeya, Greeff Yesenia, Sorour Omar, Mccallion Paul, Davis Garrison, Sorour Khaled

机构信息

Gastroenterology and Hepatology, Signature Healthcare Brockton Hospital, Brockton, USA.

Gastroenterology, University of Massachusetts Medical School Baystate, Springfield, USA.

出版信息

Cureus. 2020 Nov 19;12(11):e11573. doi: 10.7759/cureus.11573.

Abstract

BACKGROUND

Clostridium difficile infection (CDI) is a major cause of antibiotic-associated diarrhea worldwide. The incidence of sepsis has been shown to be increasing due to severe or fulminant colitis. Oral vancomycin is the treatment of choice for CDI, but it is often ineffective in patients in the intensive care unit (ICU) due to poor intestinal motility. We present a review of eight cases with severe to fulminant CDI treated with adjunctive intracolonic vancomycin (ICV) administration.

METHODS

A retrospective chart review identified patients in sepsis with severe colitis and positive Clostridium difficile toxin A or B. Patients who had failed standard therapy for CDI were given adjunctive ICV through an enteric tube, which was inserted via colonoscopy. To indicate the severity of patients, the patients selected had required vasopressor support.

RESULTS

Eight patients (37.5% females) received this adjunctive treatment; the mean age was 73.25. The average Acute Physiology and Chronic Health Evaluation (APACHE) 2 score at the time of the procedure was 39. The median length of stay was 5.5 days, with in-hospital mortality of 37.5% and an average time to death of 1.33 days from the day of colonoscopy.  Conclusion: Colonoscopic decompression and administration of vancomycin for fulminant CDI using an enteric tube can have favorable outcomes in severely ill patients whose surgical options carry a high risk of mortality. Further larger randomized controlled trials are needed to evaluate its efficacy.

摘要

背景

艰难梭菌感染(CDI)是全球抗生素相关性腹泻的主要原因。由于严重或暴发性结肠炎,脓毒症的发病率一直在上升。口服万古霉素是CDI的首选治疗方法,但由于肠道蠕动不良,它在重症监护病房(ICU)的患者中往往无效。我们对8例接受结肠内辅助万古霉素(ICV)治疗的严重至暴发性CDI患者进行了综述。

方法

一项回顾性病历审查确定了患有严重结肠炎且艰难梭菌毒素A或B呈阳性的脓毒症患者。对CDI标准治疗失败的患者通过经结肠镜插入的肠管给予辅助ICV。为了表明患者的严重程度,所选患者需要血管升压药支持。

结果

8例患者(37.5%为女性)接受了这种辅助治疗;平均年龄为73.25岁。手术时急性生理与慢性健康状况评估(APACHE)2评分的平均值为39分。中位住院时间为5.5天,住院死亡率为37.5%,从结肠镜检查当天起平均死亡时间为1.33天。结论:对于手术选择具有高死亡风险的重症患者,使用肠管进行结肠镜减压和给予万古霉素治疗暴发性CDI可取得良好效果。需要进一步开展更大规模的随机对照试验来评估其疗效。

相似文献

8
Intracolonic vancomycin for severe Clostridium difficile colitis.结肠内注射万古霉素治疗重症艰难梭菌结肠炎。
Surg Infect (Larchmt). 2013 Dec;14(6):532-9. doi: 10.1089/sur.2012.158. Epub 2013 Apr 5.

本文引用的文献

5
Burden of Clostridium difficile infection in the United States.美国艰难梭菌感染的负担
N Engl J Med. 2015 Jun 11;372(24):2369-70. doi: 10.1056/NEJMc1505190.
8
Surgical Management of Clostridium difficile Colitis.艰难梭菌性结肠炎的外科治疗
Clin Colon Rectal Surg. 2012 Dec;25(4):204-9. doi: 10.1055/s-0032-1329390.
9
Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.艰难梭菌感染的诊断、治疗和预防指南。
Am J Gastroenterol. 2013 Apr;108(4):478-98; quiz 499. doi: 10.1038/ajg.2013.4. Epub 2013 Feb 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验